Expert Discusses Docetaxel Versus Abiraterone In Hormone-Sensitive Prostate Cancer - Caroline Seymour
The management of metastatic hormone-sensitive prostate cancer continues to evolve as new findings emerge, such as results from the LATITUDE and CHAARTED studies. William K. Oh, MD, professor of medicine, hematology, medical oncology and urology, chief of the division of hematology and medical oncology, and associate director of clinical research at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, discussed treatment with abiraterone versus docetaxel in patients with prostate cancer, other remaining questions in the field, and what role immunotherapy is poised to play. “One of the biggest developments in the treatment of advanced prostate cancer over the past several years has been the management of metastatic hormone-sensitive prostate cancer,” he said.
- William K. Oh, MD, Professor, Medicine, Hematology, Medical Oncology, Urology, Chief, Division of Hematology and Medical Oncology, Associate Director, Clinical Research, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Learn more